Marion Merrell Dow's Cardizem Q.D.

Once-a-day version of calcium channel blocker diltiazem for treatment of hypertension will be the subject of FDA's Cardiovascular and Renal Drugs Advisory Committee meeting on March 14. The panel also will consider labeling implications of left ventricular hypertrophy. On March 15, the committee will discuss labeling revisions for Bristol-Myers Squibb's anti-arrhythmic Enkaid (encainide). The meeting begins both days at 9 a.m. in the Masur Auditorium on the NIH campus.